| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 12/06/2001 | WO2001091737A2 Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides |
| 12/06/2001 | WO2001091736A2 Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| 12/06/2001 | WO2001091719A1 Nasal ointment based on white petroleum jelly |
| 12/06/2001 | WO2001091588A1 Primary composition containing a lipophilic bioactive compound |
| 12/06/2001 | WO2001056532A3 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| 12/06/2001 | WO2001053351A3 Apoptin bindendes protein |
| 12/06/2001 | WO2001046392A3 Homologues of human heparanase and splice variants thereof |
| 12/06/2001 | WO2001041704A3 Method for the prevention and/or treatment of atherosclerosis |
| 12/06/2001 | WO2001034201A3 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 12/06/2001 | WO2001034138B1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 12/06/2001 | WO2001034130A9 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 12/06/2001 | WO2001032864A3 Gpcr-kd5 polypeptides and dna sequences thereof |
| 12/06/2001 | WO2001032127A3 Method and compositions for treating pulmonary diseases |
| 12/06/2001 | WO2001030381A3 Use of csf-1 inhibitors |
| 12/06/2001 | WO2001027630A3 Methods to identify compounds that modulate neuronal activity |
| 12/06/2001 | WO2001026604B1 Hair and scalp treatment method and recipes for application of this method |
| 12/06/2001 | WO2001025390B1 Water unstable foam compositions |
| 12/06/2001 | WO2001024788A3 Treating endometriosis or infertility, or improving fertility |
| 12/06/2001 | WO2001018042A3 Apoptosis proteins |
| 12/06/2001 | WO2001012662A3 Membrane associated proteins |
| 12/06/2001 | WO2001007021A3 Process for the improvement of spermatozoa fertilization activity |
| 12/06/2001 | WO2001001972A3 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 12/06/2001 | WO2000077206A3 The myostatin gene promoter and inhibition of activation thereof |
| 12/06/2001 | WO2000071101A3 Methods and compounds for inhibiting amyloid deposits |
| 12/06/2001 | WO2000061750A3 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS |
| 12/06/2001 | WO2000011166A9 14274 receptor, a g-protein coupled receptor related to the edg receptor family |
| 12/06/2001 | US20010049439 Therapeutic polymorphs of a GABA-A alpha-5 inverse agonist and pamoate formulations of the same |
| 12/06/2001 | US20010049435 Myostatin gene promoter and inhibition of activation thereof |
| 12/06/2001 | US20010049396 Symptomatic relief |
| 12/06/2001 | US20010049388 Administering a prophylactically effective amount of an HMG-CoA reductase inhibitor alone or in combination with another lipid altering agent |
| 12/06/2001 | US20010049386 Method of treating onychomycosis |
| 12/06/2001 | US20010049381 Non-immunosuppressive five-membered heterocyclic compound having a single nitrogen heteroatom, which has an N-linked ketone, diketo, thioketo, or 1-(2-(3-oxo) propene) substituent; additionally substituted with ester or amide |
| 12/06/2001 | US20010049372 Antiviral nucleoside analogues |
| 12/06/2001 | US20010049368 Administering the combination of: a PDE4 inhibitor; and a neurokinin-1 receptor antagonist or an alpha-2 adrenoreceptor agonist to minimize the side effect of nausea or emesis associated with the PDE4 inhibitor. |
| 12/06/2001 | US20010049365 Compositions and methods of treating abnormal cell proliferation |
| 12/06/2001 | US20010049362 Phospholipid compositions as anti-inflammation agents |
| 12/06/2001 | US20010049350 Adjusting the prolactin and melatonin profiles of the mammal by administering prolactin enhancers or reducers and melatonin so that the prolactin and melatonin profiles conform to or approach normal profiles |
| 12/06/2001 | US20010049349 Antioxidant enhancement of therapy for hyperproliferative conditions |
| 12/06/2001 | US20010049348 Interaction of NMDA receptor with protein tyrosine phosphatase |
| 12/06/2001 | US20010049122 For reducing inflammation, for treating an autoimmune disease, for enhancing transplantation of tissue grafts, increasing antitumor immunity, and inhibiting viral and parasitic infections |
| 12/06/2001 | US20010049121 Polypeptides and polynucleotides; drug screening, use in therapy, diagnostic assays |
| 12/06/2001 | US20010049106 ADAM (A Disintegrin And Metalloprotease) family of metalloproteases, and in addition contain thrombospondin domain (TS); treating diabetes, arthritis, cancer, solid tumors, autoimmune diseases |
| 12/06/2001 | US20010048951 Reduced concentration of carbon dioxide |
| 12/06/2001 | US20010048947 Drug delivery |
| 12/06/2001 | US20010048944 Antibiotic product, use and formulation thereof |
| 12/06/2001 | US20010048915 Decreased endogenous nitric oxide activation |
| 12/06/2001 | DE10025464A1 Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen Combined use of enzyme inhibitors for the therapy of autoimmune diseases, transplantation and tumor diseases as well as combinations of enzyme inhibitors pharmaceutical preparations comprising |
| 12/06/2001 | CA2413188A1 Petrolatum-based nose ointment |
| 12/06/2001 | CA2411666A1 Methods and compositions for producing a neurosalutary effect in a subject |
| 12/06/2001 | CA2411655A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/06/2001 | CA2411404A1 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 12/06/2001 | CA2410949A1 Novel target genes for diseases of the heart |
| 12/06/2001 | CA2410900A1 Compositions and methods for treating eye discomfort |
| 12/06/2001 | CA2410895A1 Therapeutic compounds for ovarian cancer |
| 12/06/2001 | CA2410889A1 Naaladase inhibitors for treating retinal disorders and glaucoma |
| 12/06/2001 | CA2410736A1 Alpha (2) macroglobulin receptors as a heat shock protein receptor and uses thereof |
| 12/06/2001 | CA2410734A1 Dnas encoding mammalian histamine receptor of the h4 subtype |
| 12/06/2001 | CA2410597A1 Melanocortin receptor agonists |
| 12/06/2001 | CA2410489A1 Human kcnq5 potassium channel, methods and compositions thereof |
| 12/06/2001 | CA2410480A1 Reagents and methods for identifying and modulating expression of genes regulated by retinoids |
| 12/06/2001 | CA2410470A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/06/2001 | CA2410436A1 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 12/06/2001 | CA2410087A1 Mammalian protein phosphatases identified by in-silico analysis |
| 12/06/2001 | CA2410084A1 Transporters and ion channels |
| 12/06/2001 | CA2410033A1 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 12/06/2001 | CA2409964A1 Peptide substrate identified by type bont/b botulinus toxin and use thereof for assaying and/or detecting said toxin or corresponding inhibitors |
| 12/06/2001 | CA2409932A1 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
| 12/06/2001 | CA2409927A1 Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| 12/06/2001 | CA2409311A1 Regulators of apoptosis |
| 12/06/2001 | CA2409006A1 Biciclic cyclohexylamines and their use as nmda receptor antogonists |
| 12/06/2001 | CA2408103A1 Tumor activated prodrug compounds and methods of making and using the same |
| 12/06/2001 | CA2383432A1 Therapeutic immune condition compositions and methods |
| 12/05/2001 | EP1160322A2 Human melanocyte stimulating hormone receptors |
| 12/05/2001 | EP1160254A1 Human vanilloid receptor-like proteins |
| 12/05/2001 | EP1159975A2 Anti-angiogenic compositions and methods of use |
| 12/05/2001 | EP1159974A1 Anti-angiogenic compositions and methods of use |
| 12/05/2001 | EP1159970A2 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss, comprising a nicotine receptor partial agonist and an anti-obesity agent |
| 12/05/2001 | EP1159964A2 Compositions and methods for stimulating gastrointestinal motility |
| 12/05/2001 | EP1159961A2 Treatment of tumors with compounds having RxR retinoid receptor agonist activity |
| 12/05/2001 | EP1159958A1 Vaseline-based nasal ointment |
| 12/05/2001 | EP1159756A2 Compounds for the treatment of cancer |
| 12/05/2001 | EP1159447A1 Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase |
| 12/05/2001 | EP1159445A1 Method to search for male antifertility drugs based on phgpx activity determination |
| 12/05/2001 | EP1159431A2 Human kallikrein-like genes |
| 12/05/2001 | EP1159422A1 Compositions and methods for the treatment of tumors |
| 12/05/2001 | EP1159420A1 Human pancreas and pancreatic cancer associated gene sequences and polypeptides |
| 12/05/2001 | EP1159419A1 Promotion or inhibition of angiogenesis and cardiovascularization |
| 12/05/2001 | EP1159418A2 Muc-1 antagonists and methods of treating immune disorders |
| 12/05/2001 | EP1159417A2 Polynucleotides and proteins encoded thereby |
| 12/05/2001 | EP1159300A2 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 12/05/2001 | EP1159299A1 Mammalian cytokines; related reagents and methods |
| 12/05/2001 | EP1159292A2 Compounds having growth hormone releasing activity |
| 12/05/2001 | EP1159275A2 Imidazole compounds as histamine h3 ligands |
| 12/05/2001 | EP1159008A1 Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors |
| 12/05/2001 | EP1159005A1 Pharmaceutical combination of antiviral agents |
| 12/05/2001 | EP1159004A1 Novel redox clamping agents and uses thereof |
| 12/05/2001 | EP1158976A2 VACUOLAR-TYPE (H+)-ATPase-INHIBITING COMPOUNDS, COMPOSITIONS, AND USES THEREOF |
| 12/05/2001 | EP1158972A1 Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins |
| 12/05/2001 | EP1158872A1 Dietary compositions and methods |
| 12/05/2001 | EP0863760B1 Use of antimineralocorticoid compounds against drug withdrawal syndrome |